Your browser doesn't support javascript.
loading
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial.
Friedlander, Michael; Moore, Kathleen N; Colombo, Nicoletta; Scambia, Giovanni; Kim, Byoung-Gie; Oaknin, Ana; Lisyanskaya, Alla; Sonke, Gabe S; Gourley, Charlie; Banerjee, Susana; Oza, Amit; González-Martín, Antonio; Aghajanian, Carol; Bradley, William H; Liu, Joyce; Mathews, Cara; Selle, Frédéric; Lortholary, Alain; Lowe, Elizabeth S; Hettle, Robert; Flood, Emuella; Parkhomenko, Elena; DiSilvestro, Paul.
Affiliation
  • Friedlander M; University of New South Wales Clinical School, Prince of Wales Hospital, Randwick, NSW, Australia. Electronic address: m.friedlander@unsw.edu.au.
  • Moore KN; Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, USA.
  • Colombo N; University of Milan-Bicocca, Milan, Italy; Istituto Europeo di Oncologia IRCCS, Milan, Italy.
  • Scambia G; Fondazione Policlinico Universitario A Gemelli IRCCS, Università Cattolica, Rome, Italy.
  • Kim BG; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Oaknin A; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Lisyanskaya A; St Petersburg City Oncology Dispensary, St Petersburg, Russia.
  • Sonke GS; The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Gourley C; Cancer Research UK Edinburgh Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
  • Banerjee S; The Royal Marsden NHS Foundation Trust, London, UK; Institute of Cancer Research, London, UK.
  • Oza A; Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • González-Martín A; Clínica Universidad de Navarra, Madrid, Spain.
  • Aghajanian C; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Bradley WH; Froedtert and the Medical College of Wisconsin, Milwaukee, WI, USA.
  • Liu J; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Mathews C; Women and Infants Hospital, Providence, RI, USA.
  • Selle F; Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Paris, France.
  • Lortholary A; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Paris, France; Centre Catherine de Sienne Hopital privé du Confluent, Nantes, France.
  • Lowe ES; AstraZeneca, Gaithersburg, MD, USA.
  • Hettle R; AstraZeneca, Cambridge, UK.
  • Flood E; AstraZeneca, Gaithersburg, MD, USA.
  • Parkhomenko E; PAREXEL, London, UK.
  • DiSilvestro P; Women and Infants Hospital, Providence, RI, USA.
Lancet Oncol ; 22(5): 632-642, 2021 05.
Article in En | MEDLINE | ID: mdl-33862001
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Phthalazines / Piperazines / Quality of Life / Genes, BRCA1 / Genes, BRCA2 / Mutation Type of study: Clinical_trials / Diagnostic_studies Limits: Female / Humans / Middle aged Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2021 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Phthalazines / Piperazines / Quality of Life / Genes, BRCA1 / Genes, BRCA2 / Mutation Type of study: Clinical_trials / Diagnostic_studies Limits: Female / Humans / Middle aged Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2021 Type: Article